Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic. - Wikidata - awgldk - TriplyDB

Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic.

Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic.

http://www.wikidata.org/entity/Q37310531

about

Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study.Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study Applying the triple aim to the quality agenda for anticoagulation care.

P2860

Q36126175-885EE814-F7AC-4342-8D55-A72D34E5C642 Q37240690-199E84F4-EF0D-422D-A77F-84AA961B6D21 Q42906195-0B98A812-DA46-4E5B-8145-6274A5955D7C

P2860

Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic.

http://www.wikidata.org/entity/Q37310531

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Limited English proficient pat ...... rfarin anticoagulation clinic.

@en

Limited English proficient pat ...... rfarin anticoagulation clinic.

@nl

type

label

Limited English proficient pat ...... rfarin anticoagulation clinic.

@en

Limited English proficient pat ...... rfarin anticoagulation clinic.

@nl

prefLabel

Limited English proficient pat ...... rfarin anticoagulation clinic.

@en

Limited English proficient pat ...... rfarin anticoagulation clinic.

@nl

P1433

Q37310531-EDEF76E1-FD75-4411-998C-BB0A2D4AB494

P1476

Q37310531-01973B35-EA5B-4092-92C2-CF37BB3DF3FE

P2093

Q37310531-18F8F595-B2BE-43F9-8FB5-33909554996D

Q37310531-7B3E4D8C-B336-44C1-930B-03BD549D2726

Q37310531-8241BD78-840E-410E-B486-E59034E60EB3

Q37310531-89AC1CF6-EC19-428D-AE0B-A2DD081E33F3

Q37310531-987D85EE-BB48-41C9-B111-3D28FF5D4D9B

Q37310531-BD56D793-A155-4AF2-856D-C0ED72CD160E

Q37310531-DAF37DAD-8CB2-4A87-9347-385F805AF187

P2860

Q37310531-05F2529A-46AF-4B71-8DE6-130BBEC556EE

Q37310531-06C8324B-DA89-4E0E-A3D2-3B195E5B5C81

Q37310531-1E95CC4A-F912-4CCD-8593-CA66BA750B05

Q37310531-2172F254-0DF4-47E0-A38E-77FEC13340C8

Q37310531-21A01390-F2D5-4D9C-83F4-D0C44C6957B8

Q37310531-376F1997-9328-4ECE-B27A-90E931BC42DF

Q37310531-3C6DBBEE-431E-42ED-AB68-1F0CB6508236

Q37310531-493B1FD5-C339-4A5B-9EF9-4A7922D5D9A4

Q37310531-4D36A7BA-1D77-46B3-884F-C60E544D3E11

Q37310531-4DB431A6-8296-4F2C-9759-87F9BAC5A609

P304

Q37310531-E991A651-08CA-4DC9-8530-4B4F5FEEEDC1

P31

Q37310531-FFAC83F9-044A-4E1F-AF55-94D9289B5118

P356

Q37310531-3F7F79DE-59D5-42D4-844E-7713E0CB12C5

P433

Q37310531-6D567029-AC09-4ED4-9353-9C8FF71B4156

P478

Q37310531-7E33F4D1-4657-4460-870C-3E823E1D9029

P577

Q37310531-69B40166-AB74-414C-8359-0B6291A6FA7D

P698

Q37310531-E66E5D31-9970-4B42-8C1B-B8A9AC00087D

P921

Q37310531-8ABF0F16-9745-4413-ACE1-BBF31712D052

P932

Q37310531-8A92BC31-8100-4C43-A690-5064EA06E59A

P356

JAHA.113.000170

P1433

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

P1476

Limited English proficient pat ...... rfarin anticoagulation clinic.

@en

P2093

Alexander R Green

http://www.w3.org/2001/XMLSchema#string

Clemens Hong

http://www.w3.org/2001/XMLSchema#string

Daniel E Singer

http://www.w3.org/2001/XMLSchema#string

Fátima Rodriguez

http://www.w3.org/2001/XMLSchema#string

Lenny López

http://www.w3.org/2001/XMLSchema#string

Lynn B Oertel

http://www.w3.org/2001/XMLSchema#string

Yuchiao Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

Dabigatran versus warfarin in patients with atrial fibrillation

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Calculating the benefits of a Research Patient Data Repository.

Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study.

Drug complications in outpatients

Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

P304

e000170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/JAHA.113.000170

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23832325

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

3828815

http://www.w3.org/2001/XMLSchema#string